These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24738186)

  • 21. Exon skipping with morpholino oligomers: new treatment option for cardiomyopathy in Duchenne muscular dystrophy?
    Bauer R; Katus HA; Müller OJ
    Cardiovasc Res; 2010 Feb; 85(3):409-10. PubMed ID: 20008475
    [No Abstract]   [Full Text] [Related]  

  • 22. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.
    Pires VB; Simões R; Mamchaoui K; Carvalho C; Carmo-Fonseca M
    PLoS One; 2017; 12(7):e0181065. PubMed ID: 28742140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duchenne Muscular Dystrophy Myogenic Cells from Urine-Derived Stem Cells Recapitulate the Dystrophin Genotype and Phenotype.
    Falzarano MS; D'Amario D; Siracusano A; Massetti M; Amodeo A; La Neve F; Maroni CR; Mercuri E; Osman H; Scotton C; Armaroli A; Rossi R; Selvatici R; Crea F; Ferlini A
    Hum Gene Ther; 2016 Oct; 27(10):772-783. PubMed ID: 27530229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Casimersen (Amondys 45) for Duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):e104-e105. PubMed ID: 34181634
    [No Abstract]   [Full Text] [Related]  

  • 27. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
    Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The search for a cure for Duchenne muscular dystrophy (DMD).
    Acta Myol; 2005 Dec; 24(3):169-71. PubMed ID: 16629049
    [No Abstract]   [Full Text] [Related]  

  • 30. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy.
    Nakamura A; Shiba N; Miyazaki D; Nishizawa H; Inaba Y; Fueki N; Maruyama R; Echigoya Y; Yokota T
    J Hum Genet; 2017 Apr; 62(4):459-463. PubMed ID: 27974813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy for Duchenne muscular dystrophy.
    Verhaart IE; Aartsma-Rus A
    Curr Opin Neurol; 2012 Oct; 25(5):588-96. PubMed ID: 22892952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic treatments in muscular dystrophies.
    Muntoni F; Wells D
    Curr Opin Neurol; 2007 Oct; 20(5):590-4. PubMed ID: 17885450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model.
    Hawkes N
    BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900
    [No Abstract]   [Full Text] [Related]  

  • 40. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.